Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A. Cazet AS, et al. Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6. Nat Commun. 2018. PMID: 30042390 Free PMC article. Clinical Trial.
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ. Hochgräfe F, et al. Cancer Res. 2010 Nov 15;70(22):9391-401. doi: 10.1158/0008-5472.CAN-10-0911. Epub 2010 Sep 21. Cancer Res. 2010. PMID: 20861192
Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.
O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hannigan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, Swarbrick A. O'Toole SA, et al. Cancer Res. 2011 Jun 1;71(11):4002-14. doi: 10.1158/0008-5472.CAN-10-3738. Cancer Res. 2011. PMID: 21632555
Molecular alterations in metaplastic breast carcinoma.
Cooper CL, Karim RZ, Selinger C, Carmalt H, Lee CS, O'Toole SA. Cooper CL, et al. J Clin Pathol. 2013 Jun;66(6):522-8. doi: 10.1136/jclinpath-2012-201086. Epub 2013 Jan 31. J Clin Pathol. 2013. PMID: 23372178 Review.
Therapeutic targets in triple negative breast cancer.
O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A, Oakes SR. O'Toole SA, et al. J Clin Pathol. 2013 Jun;66(6):530-42. doi: 10.1136/jclinpath-2012-201361. Epub 2013 Feb 22. J Clin Pathol. 2013. PMID: 23436929 Review.
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.
Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A. Nair R, et al. Oncogene. 2014 Jul 24;33(30):3992-4002. doi: 10.1038/onc.2013.368. Epub 2013 Sep 23. Oncogene. 2014. PMID: 24056965
438 results